Jagsonpal Pharmaceuticals Ltd. · NSE:JAGSNPHARM
Jagsonpal Pharmaceuticals — Q2 FY26 Earnings Presentation
24 slides from Jagsonpal Pharmaceuticals's earnings presentation, Nov 3, 2025
Slide 1: Exchange filing cover letter
Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91 124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com CIN. : L74899DL1978PLC009181 November 03, 2025 The Department of Corporate Services- Listing Th
Slide 2: Jagsonpal announces Q2 & H1FY26 Results
Jagsonpal Pharmaceuticals Ltd. announces Q2 & H1FY26 Results Robust H1 growth with 10% YoY uptick in Revenue & 39% PAT surge Gurugram, Nov 3, 2025: Jagsonpal Pharmaceuticals Limited (BSE: 507789, NSE: JAGSNPHARM) today announced the unaudited financial results for the quarter and half year ended Sep
Slide 3: Management commentary and about the company
Commenting on the performance for the quarter, Manish Gupta, Managing Director, Jagsonpal Pharmaceuticals Limited said, “We are pleased to report a resilient performance reflecting our continued focus on sustainable growth and operational excellence. The first half of FY26 marked a strong showing, w
Slide 4: Jagsonpal Pharmaceuticals Limited Q2 & H1FY26
Jagsonpal Pharmaceuticals 50+ Limited Years Q2 & H1FY26 Quality and Trust Investor Presentation November 2025 1
Slide 5: Safe Harbor
Safe Harbor 50+ Years This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other Quality and Trust statements relating to our future business developments and econo
Slide 6: Jagsonpal - Legacy of 'Quality and Trust' since 1964
50+ Jagsonpal - Legacy of ‘Quality and Trust’ since 1964 Years Quality and Trust Deep Market Penetration Quality culture imbibed Enduring Doctor across Operations 100% India Centric Presence across 4000+ Confidence Business towns and cities through CMOs fully complaint with Trusted by >50,000 doctor
Slide 7: Q2 & H1FY26 Highlights
Q2 & H1FY26 Highlights 4
Slide 8: Management Commentary
50+ Management Commentary Years Quality and Trust We are pleased to report a resilient performance reflecting our continued focus on sustainable growth and operational excellence. The first half of FY26 marked a strong showing, with revenue rising 10% YoY to ₹1,501 Mn, EBITDA (pre-ESOP) grew 9% YoY
Slide 9: Sustained growth trajectory – Q2 Stable, H1 robust
50+ Sustained growth trajectory – Q2 Stable, H1 robust Years Quality and Trust GST transition softens Q2, Double digit growth in H1FY26 Q2 revenue steady at ₹ 745 Mn, while H1 delivered a healthy 10.2% YoY growth to ₹ 1,501 Mn. Product Mix, Temporary GST related actions observed in Q2 Gross margins
Slide 10: Strengthening Leadership for next phase of growth
50+ Strengthening Leadership for next phase of growth Years Quality and Trust Amrut Medhekar Nirav Vora Chief Operating Officer Chief Financial Officer Amrut Medhekar has joined as Chief Operating Nirav Vora, a Chartered Accountant by Officer to drive marketing and operations across profession, has
Slide 11: Impact of GST 2.0 – a reform for accessible & affordable healthcare
Impact of GST 2.0 – a reform for accessible & affordable 50+ Years healthcare Quality and Trust Tax rate cuts on pharmaceutical Jagsonpal thrives on “Patient Aligns perfectly with nation’s products - leads to price First” approach – ensuring 100% broader objective of enforcing reduction of 6.25% to
Slide 12: Financial Highlights: Q2FY26
50+ Financial Highlights: Q2FY26 Years Quality and Trust Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT & Margin (%) Q2FY25 Q2FY26 747 745 488 472 184 181 115 126 65.3% 63.4% 15.3% 16.9% 24.6% 24.3% (All values in ₹ Mn) 9 * EBITDA and EBITDA margin is calculated Pre-ESOP
Slide 13: Financial Highlights: H1FY26
50+ Financial Highlights: H1FY26 Years Quality and Trust Revenue from Operations Gross Profit & Margin (%) EBITDA & Margin* (%) PAT & Margin (%) H1FY25 H1FY26 1,501 879 959 1,361 338 234 310 168 64.6% 63.9% 22.8% 22.5% 12.3% 15.6% (All values in ₹ Mn) * EBITDA and EBITDA margin is calculated Pre-ESO
Slide 14: Income Statement
50+ Income Statement Years (All values in ₹ Mn) Quality and Trust Particulars Q2FY26 Q2FY25 Y-O-Y H1FY26 H1FY25 Y-o-Y Revenue from Operations 745 747 -0.3% 1,501 1,361 10.2% Total Expenses 564 563 0.2% 1,163 1,051 10.7% EBITDA* 181 184 -1.9% 338 310 8.8% EBITDA Margin* 24.3% 24.6% -39 bps 22.5% 22.8
Slide 15: Key Balance Sheet Items
50+ Key Balance Sheet Items Years (All values in ₹ Mn) Quality and Trust Particulars 30-Sep-25 30-Jun-25 30-Sep-24 Shareholders Funds 2,528 2,536 1,971 Tangible Assets 6 6 10 Intangibles 818 837 894 Right of Use Assets 76 80 90 Assets Held for Sale - - 172 Financial Assets (Cash & Equivalents) 1,604
Slide 16: About the Company
50+ Years Quality and Trust About the Company 13
Slide 17: Strong Presence in Key Therapies
50+ Strong Presence in Key Therapies Years Quality and Trust Gynecology Orthopedics o 7th as per CMARC RPM in CVM o 2nd as per CMARC RPM in CVM o Reaching ~90% of the Gynecologists o Reaching ~80% of the Orthopedists nationwide, engagement with 35,000 out through consistent engagement with of 39,000
Slide 18: Building A High-impact Asset Light Model
50+ Building A High-impact Asset Light Model Years Quality and Trust Capital Intensive Activities - Out-Sourced Ideation Research & Development Contract Manufacturing PAN-India Distribution In-house Ideation For Innovative Drug Concepts. Partner with leading Partner with leading 1000+ Medical Reps f
Slide 19: Strategic Pillars
Strategic Pillars 50+ Years Quality and Trust Innovation - Niche Large, well Molecules, trained Dominant Market Work Force Share of 1000+ Medical Reps Lean Operations: Inorganic Growth Asset Light Powered by Model Strategic Acquisition 16
Slide 20: Execution Excellence across all parameters
50+ Execution Excellence across all parameters Years Quality and Trust Cash Rich and Growth Ready Capital Optimized for scalable growth Rewarding shareholders; Enhanced Payouts 351 1,456 16.1% 125 80 139 6.7% 93 252 3.5% FY22 FY25* FY22 FY24 FY25 FY22 FY25 Net Cash Position (₹ Mn) NWC (₹ Mn) % of sa
Slide 21: MySakhi Initiative Where Business Meets Social Impact
50+ MySakhi Initiative Years Where Business Meets Social Impact Quality and Trust Shaping the Future Empowering Women Through MySakhi.in Expanding outreach with self-testing kits, discounted A dedicated website offering educational lab tests, and an online forum to support women’s resources, health
Slide 22: Ongoing CSR Initiatives
50+ Ongoing CSR Initiatives Years Quality and Trust Empowering girls through hygiene and education - 14 toilets built across North India, with sanitary support and NGO-led awareness driving dignity and inclusion. 19
Slide 23: The Three Pronged Growth Strategy
The Three Pronged Growth Strategy 50+ Years Quality and Trust New Product Launch o Niche, Innovation driven o Launch 4-6 products annually, driving market engagement and revenue Coupled with Inorganic strategies along the Volume Growth way o Sales Force Empowerment o Brand acquisitions in current th
Slide 24: Thank You
Thank You Feel free to reach out to us if you have any questions JAGSONPAL PHARMACEUTICALS LTD. Corporate Office: Nimai Tower, 3rd Floor, Plot No. 412-415, Phase-IV, Udyog Vihar, Gurugram -122015, Haryana (India) cs@jagsonpal.com www.jagsonpal.com +91 124 4406710 INVESTOR RELATIONS Soumya Chhajed Em
Jagsonpal Pharmaceuticals — Q2 FY26 Earnings Presentation on 6ix